Vulvovaginal Candidiasis A Review

Abstract

“Vulvovaginal candidiasis (VVC)” is a clinical disease that is frequently seen. At least one episode of VVC occurs in at least three-fourths of all women's lifetimes. 10 to 35% of people in India have VVC. Clinical diagnosis is frequently supported by laboratory techniques. VVC should be validated through investigative methods such as culture, particularly in challenging and recurrent cases. The majority of treatment is still azoles used topically and intravenously. Oral antifungal medications are utilized in women who have predisposed risk factors or who develop recurrent VVC. Women experiencing pruritus and vulvar discomfort may apply topical steroids. A substantial risk factor is becoming pregnant. The standard of care continues to be intravaginal azoles, which can be administered beginning in the second trimester. The management of VVCs has been made more challenging by the development of non-albicans species. In order to personalize the therapy, all women who experience vaginal discharge should receive a proper diagnosis.